Priority review reduces the standard process by four months, according to a Jan. 6 release from the company. Pfizer anticipates a decision from the FDA in April.
The vaccine, intended for children 6 weeks through 17 years of age, could prevent invasive pneumococcal disease and otitis media, according to the release.
Pfizer dominates the pneumonia vaccine market, though other drugmakers are attempting to break in.
